Moderna Inc (MRNA)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Inventory turnover | 12.51 | 23.23 | 5.71 | 1.82 | 0.17 |
| Receivables turnover | — | — | — | — | — |
| Payables turnover | — | — | — | — | — |
| Working capital turnover | 0.55 | 0.94 | 2.26 | 2.55 | 0.14 |
The activity ratios of Moderna Inc indicate the efficiency of the company in managing its inventory, receivables, payables, and working capital over the years.
1. Inventory Turnover:
- Moderna Inc's inventory turnover has shown a significant improvement from 0.17 in 2020 to 12.51 in 2024. This indicates that the company has been able to turn over its inventory more frequently, which can be a positive sign of efficient inventory management and sales performance.
2. Receivables Turnover:
- The receivables turnover ratio is not available for the years provided, which may suggest that the company does not have a significant amount of accounts receivable or operates in a way that does not require detailed tracking of this metric.
3. Payables Turnover:
- Similar to receivables turnover, the payables turnover ratio is not provided for the years, which could indicate that Moderna Inc may not have a significant focus on managing its payables turnover or the data is not available.
4. Working Capital Turnover:
- Moderna Inc's working capital turnover has fluctuated over the years, ranging from 0.14 in 2020 to 2.55 in 2021 and then decreasing to 0.55 in 2024. This indicates that the company's ability to generate sales from its working capital has varied, potentially reflecting changes in the business environment or operational efficiency.
Overall, while the inventory turnover of Moderna Inc has shown a positive trend, the lack of data for receivables and payables turnover limits a comprehensive analysis of the company's overall activity ratios. Management should continue monitoring these ratios to ensure efficient operations and financial performance.
Average number of days
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 29.17 | 15.71 | 63.96 | 200.98 | 2,162.49 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
Activity ratios provide insight into how efficiently a company manages its resources and operations. Looking at Moderna Inc's activity ratios:
1. Days of Inventory on Hand (DOH):
- Moderna Inc has shown a significant improvement in managing its inventory over the years. From 2,162.49 days in 2020, the DOH has decreased to 29.17 days in 2024. This indicates that the company has been able to streamline its inventory management, reduce excess inventory, and improve its production and sales efficiency.
2. Days of Sales Outstanding (DSO):
- The data provided does not include information on Days of Sales Outstanding (DSO), which measures the average number of days it takes for a company to collect revenue after a sale. Without this data, it is not possible to assess Moderna Inc's efficiency in collecting payments from customers.
3. Number of Days of Payables:
- Similar to DSO, the data does not include information on the Number of Days of Payables, which measures how long a company takes to pay its suppliers. Without this data, it is challenging to evaluate Moderna Inc's efficiency in managing its payables and cash flow.
In summary, based on the available information, Moderna Inc has shown significant improvement in managing its inventory over the years. However, a complete assessment of the company's efficiency in collecting payments from customers and managing payables would require additional information on DSO and Number of Days of Payables.
See also:
Long-term
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Fixed asset turnover | — | — | 9.01 | 12.82 | 0.71 |
| Total asset turnover | 0.23 | 0.37 | 0.74 | 0.72 | 0.04 |
Long-term activity ratios provide insights into how effectively a company is utilizing its assets over an extended period. Looking at Moderna Inc's data for the fixed asset turnover and total asset turnover ratios over the years:
1. Fixed Asset Turnover:
- The fixed asset turnover ratio measures how efficiently a company generates sales from its fixed assets.
- In 2020, Moderna Inc had a fixed asset turnover of 0.71, indicating that it generated $0.71 in sales for every $1 invested in fixed assets.
- The ratio significantly improved in 2021, reaching 12.82, suggesting a substantial increase in sales generated from fixed assets during that period.
- In 2022, the fixed asset turnover remained high at 9.01, indicating continued efficiency in utilizing fixed assets.
- Data is not available for 2023 and 2024; hence, the trend beyond 2022 is uncertain.
2. Total Asset Turnover:
- The total asset turnover ratio indicates how efficiently a company generates sales from all its assets.
- In 2020, Moderna Inc had a total asset turnover of 0.04, signifying that it generated $0.04 in sales for every $1 of total assets.
- The ratio improved significantly in 2021 to 0.72, showing a marked increase in sales generated relative to total assets.
- In 2022 and 2023, the total asset turnover remained relatively stable at 0.74 and 0.37, respectively.
- The ratio declined in 2024 to 0.23, indicating a decrease in sales generated relative to total assets compared to the previous year.
Overall, Moderna Inc demonstrated a notable improvement in asset turnover ratios from 2020 to 2022, indicating enhanced efficiency in utilizing fixed and total assets to generate sales. However, the trend beyond 2022 is uncertain due to the lack of data for 2023 and 2024, highlighting the importance of continuous monitoring and analysis of long-term activity ratios to assess the company's performance and asset utilization efficiency.